Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationAlberto Álvarez‐Larrán, C. Besses, Chiara Paoli et al.|Haematologica|2016Cited by 149
Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients.R. Scherber, Ruben A. Mesa, A. C. Dueck et al.|Journal of Clinical Oncology|2011Cited by 4
PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)Holly L. Geyer, Ruben A. Mesa, Heidi Kosiorek et al.|Haematologica|2015Cited by 2
Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG)Holly L. Geyer, Reyes López de Mesa, Robyn M. Emanuel et al.|Unknown|2014Cited by 2
Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study GroupHolly L. Geyer, Ruben A. Mesa, R. Scherber et al.|Haematologica|2016Cited by 1